GB9913458D0 - The therapeutic use of d-threo-methylphenidate - Google Patents

The therapeutic use of d-threo-methylphenidate

Info

Publication number
GB9913458D0
GB9913458D0 GBGB9913458.7A GB9913458A GB9913458D0 GB 9913458 D0 GB9913458 D0 GB 9913458D0 GB 9913458 A GB9913458 A GB 9913458A GB 9913458 D0 GB9913458 D0 GB 9913458D0
Authority
GB
United Kingdom
Prior art keywords
methylphenidate
threo
therapeutic use
treatment
respond
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
GBGB9913458.7A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celltech Pharma Europe Ltd
Original Assignee
Medeva Europe Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medeva Europe Ltd filed Critical Medeva Europe Ltd
Priority to GBGB9913458.7A priority Critical patent/GB9913458D0/en
Publication of GB9913458D0 publication Critical patent/GB9913458D0/en
Priority to PCT/GB2000/002234 priority patent/WO2000074680A1/en
Priority to JP2001501216A priority patent/JP2003501387A/ja
Priority to DE60022033T priority patent/DE60022033T2/de
Priority to AT00940504T priority patent/ATE302006T1/de
Priority to ES00940504T priority patent/ES2243273T3/es
Priority to DK00940504T priority patent/DK1185268T3/da
Priority to AU55432/00A priority patent/AU766748B2/en
Priority to EP00940504A priority patent/EP1185268B1/en
Priority to CA002376215A priority patent/CA2376215A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
GBGB9913458.7A 1999-06-09 1999-06-09 The therapeutic use of d-threo-methylphenidate Pending GB9913458D0 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
GBGB9913458.7A GB9913458D0 (en) 1999-06-09 1999-06-09 The therapeutic use of d-threo-methylphenidate
CA002376215A CA2376215A1 (en) 1999-06-09 2000-06-08 The therapeutic use of d-threo-methylphenidate for the treatment of attention-deficit hyperactivity disorder
AT00940504T ATE302006T1 (de) 1999-06-09 2000-06-08 Therapeutische verwendung von d-threo- methylphenidate zur behandlung von aufmerksamkeitsmangel-hyperaktivitätsstörungen
JP2001501216A JP2003501387A (ja) 1999-06-09 2000-06-08 注意欠損活動亢進障害の治療のためのｄ−トレオ−メチルフェニデートの治療的使用
DE60022033T DE60022033T2 (de) 1999-06-09 2000-06-08 Therapeutische verwendung von d-threo-methylphenidate zur behandlung von aufmerksamkeitsmangel-hyperaktivitätsstörungen
PCT/GB2000/002234 WO2000074680A1 (en) 1999-06-09 2000-06-08 The therapeutic use of d-threo-methylphenidate for the treatment of attention-deficit hyperactivity disorder
ES00940504T ES2243273T3 (es) 1999-06-09 2000-06-08 Utilizacion terapeutica de d-treo-metilfenidato para el tratamiento del trastorno de hperactividad y deficit de atencion.
DK00940504T DK1185268T3 (da) 1999-06-09 2000-06-08 Terapeutisk anvendelse af D-threo-methylphenidat til behandling af opmærksomhedsforstyrrelseshyperaktivitetstilstand
AU55432/00A AU766748B2 (en) 1999-06-09 2000-06-08 The therapeutic use of d-threo-methylphenidate for the treatment of attention-deficit hyperactivity disorder
EP00940504A EP1185268B1 (en) 1999-06-09 2000-06-08 The therapeutic use of d-threo-methylphenidate for the treatment of attention-deficit hyperactivity disorder

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9913458.7A GB9913458D0 (en) 1999-06-09 1999-06-09 The therapeutic use of d-threo-methylphenidate

Publications (1)

Publication Number Publication Date
GB9913458D0 true GB9913458D0 (en) 1999-08-11

Family

ID=10855048

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB9913458.7A Pending GB9913458D0 (en) 1999-06-09 1999-06-09 The therapeutic use of d-threo-methylphenidate

Country Status (9)

Country Link
EP (1) EP1185268B1 (cg-RX-API-DMAC10.html)
JP (1) JP2003501387A (cg-RX-API-DMAC10.html)
AT (1) ATE302006T1 (cg-RX-API-DMAC10.html)
AU (1) AU766748B2 (cg-RX-API-DMAC10.html)
CA (1) CA2376215A1 (cg-RX-API-DMAC10.html)
DE (1) DE60022033T2 (cg-RX-API-DMAC10.html)
ES (1) ES2243273T3 (cg-RX-API-DMAC10.html)
GB (1) GB9913458D0 (cg-RX-API-DMAC10.html)
WO (1) WO2000074680A1 (cg-RX-API-DMAC10.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5837284A (en) 1995-12-04 1998-11-17 Mehta; Atul M. Delivery of multiple doses of medications
US6486177B2 (en) 1995-12-04 2002-11-26 Celgene Corporation Methods for treatment of cognitive and menopausal disorders with D-threo methylphenidate
US6962997B1 (en) 1997-05-22 2005-11-08 Celgene Corporation Process and intermediates for resolving piperidyl acetamide steroisomers
CA2595400C (en) 2005-01-20 2017-01-17 Institute For Molecular Medicine, Inc. Methylphenidate derivatives and their use in the treatment of angiogenic diseases and conditions
JP5856843B2 (ja) 2008-05-27 2016-02-10 アンピオ ファーマシューティカルズ，インコーポレイテッド ジケトピペラジンを用いた医薬組成物
EP3349853B1 (en) 2015-09-15 2023-12-20 Praxis Bioresearch, LLC Prodrugs of fencamfamine

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9514451D0 (en) * 1995-07-14 1995-09-13 Chiroscience Ltd Sustained-release formulation
US5908850A (en) * 1995-12-04 1999-06-01 Celgene Corporation Method of treating attention deficit disorders with d-threo methylphenidate
US5837284A (en) * 1995-12-04 1998-11-17 Mehta; Atul M. Delivery of multiple doses of medications
US5922736A (en) * 1995-12-04 1999-07-13 Celegene Corporation Chronic, bolus administration of D-threo methylphenidate
MX9805870A (cg-RX-API-DMAC10.html) * 1996-01-22 1999-01-31
US6210705B1 (en) * 1997-12-15 2001-04-03 Noven Pharmaceuticals, Nc. Compositions and methods for treatment of attention deficit disorder and attention deficit/hyperactivity disorder with methylphenidate
US6025502A (en) * 1999-03-19 2000-02-15 The Trustees Of The University Of Pennsylvania Enantopselective synthesis of methyl phenidate

Also Published As

Publication number Publication date
WO2000074680A1 (en) 2000-12-14
EP1185268B1 (en) 2005-08-17
AU766748B2 (en) 2003-10-23
ATE302006T1 (de) 2005-09-15
EP1185268A1 (en) 2002-03-13
ES2243273T3 (es) 2005-12-01
DE60022033T2 (de) 2006-03-30
AU5543200A (en) 2000-12-28
JP2003501387A (ja) 2003-01-14
CA2376215A1 (en) 2000-12-14
DE60022033D1 (de) 2005-09-22

Similar Documents

Publication Publication Date Title
IL151164A0 (en) Azacyclic compounds for use in the treatment of serotonin related diseases
SG158731A1 (en) Novel medicament compositions, based on anticholinergically effective compounds and beta-mimetics
NO2013002I1 (no) Aklidinium haogenid (Aklidinium bromid)
GEP20094759B (en) Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors
PT1147110E (pt) Derivados de pirazino (aza)-indol
MXPA02011304A (es) Derivados de piperidina farmaceuticamente activos, en partiular como moduladores de la actividad del receptor de la quimocina.
DE60008369D1 (en) N-cyanomethylamide als protease-inhibitoren
HUP0000873A2 (hu) A levobupivakain arcsebészeti alkalmazása
MXPA04004503A (es) Derivados de piperina y su uso como moduladores de actividad receptora de quimiocina (especialmente ccr5).
DK1000029T3 (da) Norcisaprid nyttig med hensyn til 5-HT3- og 5-HT4- medierede lidelser
TW200508199A (en) Novel compound
PL1697005T3 (pl) Kombinacja flupirtyny i tramadolu
MY103210A (en) Arylpiperazinyl-alkylene-phenyl-heterocyclic compounds.
ATE302006T1 (de) Therapeutische verwendung von d-threo- methylphenidate zur behandlung von aufmerksamkeitsmangel-hyperaktivitätsstörungen
PT783495E (pt) Derivados de quinoxalina uteis em terapia
AP2000002017A0 (en) Salts of paroxetine.
EP1152762B8 (de) Verwendung von desoxypeganin zur behandlung von alzheimerischer demenz
NZ536111A (en) Statin therapy for enhancing cognitive maintenance
MXPA03006742A (es) Uso de buprenorfina para la terapia de la incontinencia urinaria.
BG105984A (bg) Използване на озанетант за приготвяне на лекарствени средства полезни за лечение на разстройства на настроението
AU2003270292A1 (en) Combined use of methylphenidate and melatonin for treating attention-deficit hyperactive disorder
NO20010984L (no) Anvendelse av R(+)-<alfa>-(2,3-dimetoksyfenyl)-1-[2-(4-fluorfenyl)etyl]-4-piperidinmetanol for behandling av sovnforstyrrelser
NO20055998L (no) Diarylmetylidenpiperidinderivater, preparater derav og anvendelse derav
YU62101A (sh) Terapeutski agensi za tretiranje povremenog hramanja
WO2002038167A3 (en) Use of factor xiii for treating hemophilia b